NASDAQ: LFCR
Lifecore Biomedical Inc Stock

$7.89-0.33 (-4.01%)
Updated Nov 13, 2025
LFCR Price
$7.89
Fair Value Price
N/A
Market Cap
$295.61M
52 Week Low
$4.76
52 Week High
$8.85
P/E
N/A
P/B
-28.05x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-18.83
Operating Cash Flow
N/A
Beta
1.13
Next Earnings
Jan 1, 2026
Ex-Dividend
N/A
Next Dividend
N/A

LFCR Overview

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. It operates through Lifecore, Curation Foods, and Other segments. The Lifecore segment engages in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, including technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. This segment sells its non-HA products for medical use primarily in the ophthalmic, orthopedic, and other markets. The Curation Foods segment engages in processing, marketing, and selling of olive oils and wine vinegars under the O brand; and guacamole and avocado food products under the Yucatan and Cabo Fresh brands, as well as various private labels. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was incorporated in 1986 and is headquartered in Santa Maria, California.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine LFCR's potential to beat the market

CHold
  • Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More

Zen Rating Component Grades

C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Pharmaceutical

Industry Rating
B
LFCR
Ranked
#33 of 58

Top Ranked Stocks in Industry

View Top Pharmaceutical Stocks

Be the first to know about important LFCR news, forecast changes, insider trades & much more!

LFCR News

Overview

Due Diligence Score

Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how LFCR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

LFCR's short-term assets ($83.93M) exceed its short-term liabilities ($29.96M)
Short-term Liabilities Financials
LFCR's long-term liabilities ($168.46M) exceed its short-term assets ($83.93M)
Long-term Liabilities Financials
LFCR's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
There are 30 more LFCR due diligence checks available for Premium users.

Valuation

LFCR price to earnings (PE)

For valuing profitable companies with steady earnings

Company
0x
Industry
23.99x
Market
44.95x

LFCR price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
-28.05x
Industry
2.18x

LFCR's financial health

Profit margin

Revenue
$31.1M
Net Income
-$10.0M
Profit Margin
-35.1%

Assets to liabilities

Assets
$235.2M
Liabilities
$198.4M
Debt to equity
-18.83
LFCR's short-term assets ($83.93M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
LFCR's long-term liabilities ($168.46M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
LFCR's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
LFCR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
$1.8M
Investing
-$1.7M
Financing
-$1.4M

LFCR vs Pharmaceutical Stocks

TickerZen RatingMarket Cap1d %P/EP/B
LFCRC$295.61M-4.01%N/A-28.05x
BIOAD$276.80M-3.62%0.57x1.00x
ACBF$246.95M-3.09%-5.91x0.65x
TKNOC$237.13M-0.67%-13.03x3.26x
CGCC$376.42M-7.56%-0.55x0.72x

Lifecore Biomedical Stock FAQ

What is Lifecore Biomedical's quote symbol?

(NASDAQ: LFCR) Lifecore Biomedical trades on the NASDAQ under the ticker symbol LFCR. Lifecore Biomedical stock quotes can also be displayed as NASDAQ: LFCR.

If you're new to stock investing, here's how to buy Lifecore Biomedical stock.

What is the 52 week high and low for Lifecore Biomedical (NASDAQ: LFCR)?

(NASDAQ: LFCR) Lifecore Biomedical's 52-week high was $8.85, and its 52-week low was $4.76. It is currently -10.85% from its 52-week high and 65.76% from its 52-week low.

How much is Lifecore Biomedical stock worth today?

(NASDAQ: LFCR) Lifecore Biomedical currently has 37,466,352 outstanding shares. With Lifecore Biomedical stock trading at $7.89 per share, the total value of Lifecore Biomedical stock (market capitalization) is $295.61M.

Lifecore Biomedical stock was originally listed at a price of $3.50 in Dec 31, 1997. If you had invested in Lifecore Biomedical stock at $3.50, your return over the last 27 years would have been 125.43%, for an annualized return of 3.06% (not including any dividends or dividend reinvestments).

How much is Lifecore Biomedical's stock price per share?

(NASDAQ: LFCR) Lifecore Biomedical stock price per share is $7.89 today (as of Nov 13, 2025).

What is Lifecore Biomedical's Market Cap?

(NASDAQ: LFCR) Lifecore Biomedical's market cap is $295.61M, as of Nov 14, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Lifecore Biomedical's market cap is calculated by multiplying LFCR's current stock price of $7.89 by LFCR's total outstanding shares of 37,466,352.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.